Key result
Angiotensin-(1-7) and ACE2 play a cardioprotective role following ischemia/reperfusion and may represent a novel therapy for heart failure following myocardial infarction.
Answers are grounded in this paper and cite their sources.
Increasing ACE2 activity and the production of angiotensin-(1-7) may represent a novel therapeutic strategy for heart failure following myocardial infarction.
Angiotensin-(1-7), a biologically active peptide of the renin-angiotensin system, is cardioprotective following ischemia/reperfusion and reduces cardiac hypertrophy. A recently discovered homolog of angiotensin converting enzyme (ACE), ACE2, is present in the heart and synthesizes angiotensin-(1-7) from angiotensin II. Cardiac ACE2 is elevated following inhibition of Ang II subtype 1 (AT(1)) receptors or blockade of angiotensin II production, suggesting that angiotensin-(1-7) plays a role in the beneficial effects of AT(1) receptor antagonists and ACE inhibitors in the heart. An increase in ACE2 activity and the production of angiotensin-(1-7) may thus represent a novel therapy for heart failure following myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Tallant et al. (2006) conducted a review in Heart failure following myocardial infarction. Angiotensin-(1-7) and ACE2 was evaluated. Angiotensin-(1-7) and ACE2 play a cardioprotective role following ischemia/reperfusion and may represent a novel therapy for heart failure following myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: